Overview

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: 1. To determine the efficacy of combining Interferon Alpha (IFN) with etoposide for the treatment of relapsed osteosarcoma. 2. To determine if IFN alters the plasma pharmacokinetics of etoposide. 3. To determine the toxicities of IFN and etoposide when administered together. 4. To determine IFN blood levels following combination therapy.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Schering-Plough
Treatments:
Etoposide
Etoposide phosphate
Interferon-alpha
Interferons